138 related articles for article (PubMed ID: 2113224)
1. The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment.
Dahl K; Walstad RA; Widerøe TE
Nephrol Dial Transplant; 1990; 5(4):275-81. PubMed ID: 2113224
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD).
Fuiano G; Sepe V; Viscione M; Nani E; Conte G
Perit Dial Int; 1989; 9(4):273-5. PubMed ID: 2488380
[TBL] [Abstract][Full Text] [Related]
3. Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.
Searle M; Raman GV
Clin Nephrol; 1985 May; 23(5):241-4. PubMed ID: 4006333
[TBL] [Abstract][Full Text] [Related]
4. The effect of peritonitis on the distribution of cefuroxime in patients undergoing continuous ambulatory peritoneal dialysis.
McIntosh ME; Smith WG; Junor BJ; Forrest G; Brodie MJ
Scott Med J; 1984 Apr; 29(2):117-8. PubMed ID: 6531683
[No Abstract] [Full Text] [Related]
5. Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis.
Chan MK; Browning AK; Poole CJ; Matheson LA; Li CS; Baillod RA; Moorhead JF
Nephron; 1985; 41(2):161-5. PubMed ID: 4047273
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis.
Harford AM; Sica DA; Tartaglione T; Polk RE; Dalton HP; Poynor W
Nephron; 1986; 43(3):217-22. PubMed ID: 3724930
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
Grabe DW; Bailie GR; Eisele G; Frye RF
Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
9. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
[TBL] [Abstract][Full Text] [Related]
10. Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.
McIntosh ME; Smith WG; Junor BJ; Forrest G; Brodie MJ
Eur J Clin Pharmacol; 1985; 28(2):187-91. PubMed ID: 3987798
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of single dose intravenous vancomycin in CAPD peritonitis.
Whitby M; Edwards R; Aston E; Finch RG
J Antimicrob Chemother; 1987 Mar; 19(3):351-7. PubMed ID: 3571051
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Choi KC; Jeong TK; Lee SC; Kim SW; Kim NH; Lee KY
Adv Perit Dial; 1998; 14():173-9. PubMed ID: 10649719
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.
Bonati M; Traina GL; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
Br J Clin Pharmacol; 1988 Jun; 25(6):761-5. PubMed ID: 2974299
[TBL] [Abstract][Full Text] [Related]
14. Transperitoneal movement and pharmacokinetics of cefotiam and cefsulodin in patients on continuous ambulatory peritoneal dialysis.
Brouard R; Tozer TN; Merdjan H; Guillemin A; Baumelou A
Clin Nephrol; 1988 Oct; 30(4):197-206. PubMed ID: 3214965
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.
Stamatiadis D; Papaioannou MG; Giamarellos-Bourboulis EJ; Marinaki S; Giamarellou H; Stathakis CP
Perit Dial Int; 2003; 23(2):127-31. PubMed ID: 12713078
[TBL] [Abstract][Full Text] [Related]
16. Peritonitis complicating continuous ambulatory peritoneal dialysis in Nottingham 1983-1988.
Wilcox MH; Finch RG; Burden RP; Morgan AG
J Med Microbiol; 1991 Mar; 34(3):137-41. PubMed ID: 2010903
[TBL] [Abstract][Full Text] [Related]
17. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function.
Lui SL; Cheng SW; Ng F; Ng SY; Wan KM; Yip T; Tse KC; Lam MF; Lai KN; Lo WK
Kidney Int; 2005 Nov; 68(5):2375-80. PubMed ID: 16221243
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Low CL; Gopalakrishna K; Lye WC
J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
[TBL] [Abstract][Full Text] [Related]
19. Long-term changes in transperitoneal water transport during continuous ambulatory peritoneal dialysis.
Wideröe TE; Smeby LC; Mjåland S; Dahl K; Berg KJ; Wessel Aas T
Nephron; 1984; 38(4):238-47. PubMed ID: 6514073
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
